Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 15/20 | 0.36 |
| ▸ | DRD4 | P21917 | 10/20 | 0.36 |
| ▸ | DRD3 | P35462 | 6/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 3/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CCR3 | P51677 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7870209 | 0.99 | DRD2 (0.35) | DRD2DRD4DRD3HRH4HTR1A | |
| SCHEMBL7871562 | 0.92 | ALDH1A1 (0.39) | DRD2DRD4DRD3HRH4HTR1A | |
| Hydrochloric Acid SCHEMBL7868678 | 0.91 | ALDH1A1 (0.38) | DRD2DRD4DRD3HRH4HTR1A | |
| SCHEMBL7871572 | 0.83 | L3MBTL1 (0.31) | DRD2DRD4L3MBTL1HDAC8 | |
| Hydrochloric Acid SCHEMBL7872401 | 0.82 | L3MBTL1 (0.31) | DRD2DRD4L3MBTL1HDAC8 | |
| SCHEMBL7875400 | 0.79 | IDO1 (0.36) | DRD2HTR1AHTR2AL3MBTL1 | |
| SCHEMBL7871610 | 0.78 | NPY5R (0.37) | DRD2HTR1AHTR2AL3MBTL1 | |
| SCHEMBL7872422 | 0.75 | IDO1 (0.36) | DRD2HTR1AHTR2AHTR2C | |
| SCHEMBL7868706 | 0.74 | ALDH1A1 (0.37) | DRD2DRD4DRD3HDAC8 | |
| Hydrochloric Acid SCHEMBL7871554 | 0.73 | ALDH1A1 (0.36) | DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010051631-A1 | Tricyclic compounds, their production and use | TAKATANI MUNEO (JP) | 2001-12-13 | — | — | US | disclosed |
| US-6251905-B1 | Tricyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| US-5958942-A | HAVING EXCELLENT PDGF-INHIBITING ACTIVITIES, ANTIHYPERTENSIVE ACTIVITIES, ACTIVITIES OF AMELIORATING RENAL DISEASES AND ACTIVITIES OF LOWERING LIPID LEVEL. | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-28 | — | — | US | disclosed |
| EP-0771319-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1997-05-07 | — | — | EP | disclosed |
| WO-1996002542-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051631-A1 | Tricyclic compounds, their production and use | PDGFA, HGF, REN | DRD2 1720/4885DRD4 1994/4885DRD3 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.